Daniel A Erlanson

Summary

Affiliation: Sunesis Pharmaceuticals
Country: USA

Publications

  1. ncbi In situ assembly of enzyme inhibitors using extended tethering
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Nat Biotechnol 21:308-14. 2003
  2. ncbi Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    J Am Chem Soc 125:5602-3. 2003
  3. ncbi Tethering: fragment-based drug discovery
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Annu Rev Biophys Biomol Struct 33:199-223. 2004
  4. ncbi Fragment-based drug discovery
    Daniel A Erlanson
    Sunesis Pharmaceuticals Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    J Med Chem 47:3463-82. 2004
  5. ncbi Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Curr Opin Chem Biol 8:399-406. 2004
  6. ncbi Fragment-based ligand discovery meets phage display
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    ACS Chem Biol 2:779-82. 2007
  7. ncbi Fragment-based lead discovery: a chemical update
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Curr Opin Biotechnol 17:643-52. 2006
  8. ncbi Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design
    Ingrid C Choong
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    J Med Chem 45:5005-22. 2002
  9. ncbi Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry
    Mark T Cancilla
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 18:3978-81. 2008
  10. ncbi Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue
    Stig K Hansen
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Biochemistry 44:7704-12. 2005

Collaborators

Detail Information

Publications14

  1. ncbi In situ assembly of enzyme inhibitors using extended tethering
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Nat Biotechnol 21:308-14. 2003
    ..One molecule derived from this approach inhibited apoptosis in cells...
  2. ncbi Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    J Am Chem Soc 125:5602-3. 2003
    ..We applied this approach to the anti-diabetic protein PTP1B to discover a pY mimetic which belongs to a new molecular class and which binds in a novel fashion...
  3. ncbi Tethering: fragment-based drug discovery
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Annu Rev Biophys Biomol Struct 33:199-223. 2004
    ....
  4. ncbi Fragment-based drug discovery
    Daniel A Erlanson
    Sunesis Pharmaceuticals Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    J Med Chem 47:3463-82. 2004
  5. ncbi Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Curr Opin Chem Biol 8:399-406. 2004
    ..We also describe how this technique can facilitate fragment-based lead discovery and help overcome some of the limitations of traditional screening methods...
  6. ncbi Fragment-based ligand discovery meets phage display
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    ACS Chem Biol 2:779-82. 2007
    ..A recent advance combines the concepts of fragment-based ligand discovery with phage-display technology to yield bivalent kinase inhibitors with high potency and specificity...
  7. ncbi Fragment-based lead discovery: a chemical update
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Curr Opin Biotechnol 17:643-52. 2006
    ....
  8. ncbi Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design
    Ingrid C Choong
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    J Med Chem 45:5005-22. 2002
    ..A high-resolution X-ray cocrystal structure of 4 and 66b supports the predicted binding modes of our compounds with caspase-3...
  9. ncbi Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry
    Mark T Cancilla
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 18:3978-81. 2008
    ..The binding mode of a noncovalent inhibitor has been further characterized through crystallography...
  10. ncbi Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue
    Stig K Hansen
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Biochemistry 44:7704-12. 2005
    ..These findings illustrate that targeting cysteine residues outside catalytic sites may be exploited in allosterically regulating enzymes. Moreover, these results suggest a new strategy for inhibiting a promising diabetes target...
  11. ncbi Allosteric inhibition of protein tyrosine phosphatase 1B
    Christian Wiesmann
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Nat Struct Mol Biol 11:730-7. 2004
    ..Allosteric inhibition is a promising strategy for targeting PTP1B and constitutes a mechanism that may be applicable to other tyrosine phosphatases...
  12. ncbi Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery
    Daniel A Erlanson
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Blvd, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 21:3078-83. 2011
    ..With subsequent medicinal chemistry, this led to the discovery of a potent and highly selective inhibitor of PDK1, which binds in the 'DFG-out' conformation...
  13. ncbi Selective reduction of peptide isothiazolidin-3-ones
    Timothy P Shiau
    Sunesis Pharmaceuticals, Inc, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Org Lett 8:5697-9. 2006
    ..We synthesized a coumarin-based thioacid nucleophile which shows a marked fluorescence increase after addition to an isothiazolidinone sulfenamide bond. [structure: see text]..
  14. ncbi Introduction to fragment-based drug discovery
    Daniel A Erlanson
    Carmot Therapeutics, Inc, San Francisco, CA 94158, USA
    Top Curr Chem 317:1-32. 2012
    ..It will introduce some of the key concepts, set the stage for the chapters to follow, and demonstrate how X-ray crystallography plays a central role in fragment identification and advancement...